Omeros (OMER) Stock Price, News & Analysis

Company Overview

Omeros Corporation is a biopharmaceutical company focused on discovering, developing and commercializing therapies for diseases involving the complement system, immune system and inflammation. The company is headquartered in Seattle, Washington, and was founded in 1994 by Gregory A. Demopulos, M.D., who serves as its chairman and chief executive officer.

Omeros’ marketed product, OMIDRIA, is an ophthalmic solution containing phenylephrine and ketorolac. It is used during cataract surgery and other lens replacement procedures to help maintain pupil size and reduce postoperative pain and inflammation. The company has also developed earlier-stage drug candidates targeting immune-mediated and complement-related disorders.

Its pipeline has included narsoplimab, an investigational inhibitor of the lectin pathway of the complement system, and OMS906, an investigational antibody designed to inhibit MASP-3 and regulate the alternative pathway of complement. Omeros has conducted clinical development activities in the United States and other jurisdictions, with its research programs focused primarily on rare and serious diseases for which existing treatment options may be limited.

Key Stats

• Today's Range: $17.42 to $18.30
• 50-Day Range: $9.22 to $19.39
• 52-Week Range: $3.94 to $19.65
• Volume: 1.63 million shs
• Average Volume: 1.49 million shs
• Market Capitalization: $1.26 billion
• P/E Ratio: 13.64
• Dividend Yield: N/A
• Price Target: $38.00
• Consensus Rating: Moderate Buy

Omeros Stock Analysis - MarketRank™

Omeros scored higher than 78% of companies evaluated by MarketBeat, and ranked 91st out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omeros has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 2 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Omeros has a consensus price target of $38.00, representing about 117.6% upside from its current price of $17.46.

Amount of Analyst Coverage

Omeros has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Omeros are expected to grow in the coming year, from ($0.37) to $1.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omeros is 13.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.01.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omeros is 13.64, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.84.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

19.69% of the float of Omeros has been sold short.

Short Interest Ratio / Days to Cover

Omeros has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Omeros has recently decreased by 12.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omeros does not currently pay a dividend.

Dividend Growth

Omeros does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.11

News Sentiment

Omeros has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Omeros this week, compared to 5 articles on an average week.

Search Interest

Only 7 people have searched for OMER on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Omeros insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,780,205.00 in company stock.

Percentage Held by Insiders

10.50% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

48.79% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OMER
• CIK: 1285819
• Web: www.omeros.com
• Phone: (206) 676-5000
• Fax: 206-676-5005
• Employees: 175
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Omeros: $38.00
• High Price Target: $45.00
• Low Price Target: $33.00
• Potential Upside/Downside: +117.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.28
• Trailing P/E Ratio: 13.64
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.35 million
• Net Margins: N/A
• Pretax Margin: 308.76%
• Return on Equity: -164.92%
• Return on Assets: 69.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.95
• Quick Ratio: 1.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $1.79 per share
• Price / Cash Flow: 9.77
• Book Value: ($1.71) per share
• Price / Book: -10.21

Miscellaneous

• Outstanding Shares: 72,390,000
• Free Float: 64,787,000
• Market Cap: $1.26 billion
• Optionable: Optionable
• Beta: 2.60